Astria Therapeutics

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Earnings data Q1 2024

Astria Therapeutics reports positive Phase Ia data and financial strength

Astria Therapeutics presented promising developments in their pipeline, with a focus on STAR-0215 and STAR-310. Financially, the company is well-positioned with significant cash and short-term investments. However, they face challenges in accelerating the Phase III timeline and addressing potential enrollment and regulatory hurdles. Despite these challenges, the company sees opportunities in expanding global trials and leveraging community support for enrollment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Th.

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of Astria's common stock on April 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grant.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate a favorable safety and tolerability profile, mean monthly atta.

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “We have strong conviction in the potential for STAR-0215 to be the first-choice preventative therapy for HAE,” said Jill C. Milne, Chief Executive Officer at Astria Therapeutics. “Our final.

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of.

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th at 9:20am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webca.

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of 10,340,000 shares of its common stock. Each share of common stock is being sold at a price of $12.09. The aggregate gross proceeds of the offering are expected to be approximately $125 million,.

Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering

Elicio Therapeutics Inc

HighPeak Energy Inc

Syros Pharmaceuticals

Unifi

Verrica Pharmaceuticals Inc

As the year wound to a close, biotechs were in focus among the notable insider purchases.

Here's What Insiders Are Buying to Wrap Up the Year

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday, December 3 at 10:00am ICT in Bangkok, Thailand. Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutics, will present a poster titled, “Support for STAR-0215 Administered.

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR-0310 at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30, at 8:45am ET in Miami, FL. A webcast of the presentation can be accessed at the following link.

Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.

Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We are realizing our vision of growing an allergy and immunology company with a pipeline of potential best-in-class therapies,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria.

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Astria Therapeutics (ATXS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in Anaheim, California that demonstrated STAR-0215's profile as a potential HAE preventative therapy with robust attack suppression and low treatment burden in healthy adult subjects. These dat.

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR-0310 at the Jefferies London Healthcare Conference on Wednesday, November 15, at 10:30am GMT in London, UK. A webcast of the presentation can be accessed at the following link: h.

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast.

Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.

Astria Therapeutics strikes exclusive license agreement for dermatitis treatment portfolio

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of (i) 8,253,895 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock, and (ii) to certain investors in lieu of common sto.

Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-0310,.

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer half-life than existing HAE treatments, potentially offering a longer duration of action. The company is currently conducting a proof of concept trial for STAR-0215 in HAE patients, with results expected in mid-2024.

Astria Therapeutics: Too Much Baggage, Too Strong A Competition

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will be participating in two upcoming investor conferences: Noah Clauser, Chief Financial Officer, will present a corporate overview and information on STAR-0215 at the H.C. Wainwright 25th Annual Global Investment C.

Astria Therapeutics to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215's profile as a potential long-acting therapy for hereditary angioedema (HAE) dosed once every three or six months has been published in the Journal of Pharmacology and Experimental.

Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 HAEi Regional EMEA Conference in Munich, Germany from Septe.

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We are making excellent progress with our STAR-0215 program and are proud to have received Fast Track Designation for the treatmen.

News for Astria Therapeutics Stock (ATXS)